Literature DB >> 18382667

DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70.

Sara Batelli1, Diego Albani, Raffaela Rametta, Letizia Polito, Francesca Prato, Marzia Pesaresi, Alessandro Negro, Gianluigi Forloni.   

Abstract

BACKGROUND: Parkinson's disease (PD) is a neurodegenerative pathology whose molecular etiopathogenesis is not known. Novel contributions have come from familial forms of PD caused by alterations in genes with apparently unrelated physiological functions. The gene coding for alpha-synuclein (alpha-syn) (PARK1) has been investigated as alpha-syn is located in Lewy bodies (LB), intraneuronal inclusions in the substantia nigra (SN) of PD patients. A-syn has neuroprotective chaperone-like and antioxidant functions and is involved in dopamine storage and release. DJ-1 (PARK7), another family-PD-linked gene causing an autosomal recessive form of the pathology, shows antioxidant and chaperone-like activities too. METHODOLOGY/PRINCIPAL
FINDINGS: The present study addressed the question whether alpha-syn and DJ-1 interact functionally, with a view to finding some mechanism linking DJ-1 inactivation and alpha-syn aggregation and toxicity. We developed an in vitro model of alpha-syn toxicity in the human neuroblastoma cell line SK-N-BE, influencing DJ-1 and alpha-syn intracellular concentrations by exogenous addition of the fusion proteins TAT-alpha-syn and TAT-DJ-1; DJ-1 was inactivated by the siRNA method. On a micromolar scale TAT-alpha-syn aggregated and triggered neurotoxicity, while on the nanomolar scale it was neuroprotective against oxidative stress (induced by H(2)O(2) or 6-hydroxydopamine). TAT-DJ-1 increased the expression of HSP70, while DJ-1 silencing made SK-N-BE cells more susceptible to oxidative challenge, rendering TAT-alpha-syn neurotoxic at nanomolar scale, with the appearance of TAT-alpha-syn aggregates. CONCLUSION/SIGNIFICANCE: DJ-1 inactivation may thus promote alpha-syn aggregation and the related toxicity, and in this model HSP70 is involved in the antioxidant response and in the regulation of alpha-syn fibril formation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18382667      PMCID: PMC2270347          DOI: 10.1371/journal.pone.0001884

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  38 in total

1.  Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions.

Authors:  Sreeganga Chandra; Francesco Fornai; Hyung-Bae Kwon; Umar Yazdani; Deniz Atasoy; Xinran Liu; Robert E Hammer; Giuseppe Battaglia; Dwight C German; Pablo E Castillo; Thomas C Südhof
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-01       Impact factor: 11.205

2.  Detection of novel intracellular alpha-synuclein oligomeric species by fluorescence lifetime imaging.

Authors:  Jochen Klucken; Tiago F Outeiro; Paul Nguyen; Pamela J McLean; Bradley T Hyman
Journal:  FASEB J       Date:  2006-10       Impact factor: 5.191

3.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.

Authors:  R Krüger; W Kuhn; T Müller; D Woitalla; M Graeber; S Kösel; H Przuntek; J T Epplen; L Schöls; O Riess
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

4.  Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1.

Authors:  Matthew S Goldberg; Antonio Pisani; Marian Haburcak; Timothy A Vortherms; Tohru Kitada; Cinzia Costa; Youren Tong; Giuseppina Martella; Anne Tscherter; Andrea Martins; Giorgio Bernardi; Bryan L Roth; Emmanuel N Pothos; Paolo Calabresi; Jie Shen
Journal:  Neuron       Date:  2005-02-17       Impact factor: 17.173

5.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

Review 6.  Parkinsonism genes: culprits and clues.

Authors:  Asa Abeliovich; M Flint Beal
Journal:  J Neurochem       Date:  2006-07-06       Impact factor: 5.372

Review 7.  Alpha-synuclein and presynaptic function: implications for Parkinson's disease.

Authors:  Simon Lykkebo; Poul Henning Jensen
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

Review 8.  Delivery of bioactive molecules into the cell: the Trojan horse approach.

Authors:  Gunnar P H Dietz; Mathias Bähr
Journal:  Mol Cell Neurosci       Date:  2004-10       Impact factor: 4.314

9.  Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70.

Authors:  Diego Albani; Erika Peverelli; Raffaela Rametta; Sara Batelli; Lorenzo Veschini; Alessandro Negro; Gianluigi Forloni
Journal:  FASEB J       Date:  2004-09-02       Impact factor: 5.191

10.  DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation.

Authors:  Shoshana Shendelman; Alan Jonason; Cecile Martinat; Thomas Leete; Asa Abeliovich
Journal:  PLoS Biol       Date:  2004-10-05       Impact factor: 8.029

View more
  50 in total

Review 1.  The role of cysteine oxidation in DJ-1 function and dysfunction.

Authors:  Mark A Wilson
Journal:  Antioxid Redox Signal       Date:  2011-01-14       Impact factor: 8.401

2.  Engineered disulfide bonds restore chaperone-like function of DJ-1 mutants linked to familial Parkinson's disease.

Authors:  Todd Logan; Lindsay Clark; Soumya S Ray
Journal:  Biochemistry       Date:  2010-07-13       Impact factor: 3.162

Review 3.  Molecular chaperones in Parkinson's disease--present and future.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

4.  Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy.

Authors:  Kiren Ubhi; Edward Rockenstein; Michael Mante; Christina Patrick; Anthony Adame; Monica Thukral; Clifford Shults; Eliezer Masliah
Journal:  Neuroreport       Date:  2008-08-27       Impact factor: 1.837

5.  Upregulated Parkin expression protects mitochondrial homeostasis in DJ-1 konckdown cells and cells overexpressing the DJ-1 L166P mutation.

Authors:  Chunyan Chang; Guolu Wu; Peiye Gao; Ling Yang; Wen Liu; Ji Zuo
Journal:  Mol Cell Biochem       Date:  2013-11-16       Impact factor: 3.396

6.  α-synuclein expression from a single copy transgene increases sensitivity to stress and accelerates neuronal loss in genetic models of Parkinson's disease.

Authors:  Jason F Cooper; Katie K Spielbauer; Megan M Senchuk; Saravanapriah Nadarajan; Monica P Colaiácovo; Jeremy M Van Raamsdonk
Journal:  Exp Neurol       Date:  2018-09-05       Impact factor: 5.330

Review 7.  Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases.

Authors:  Nathan P Staff; David T Jones; Wolfgang Singer
Journal:  Mayo Clin Proc       Date:  2019-05       Impact factor: 7.616

8.  DJ-1 deficient mice demonstrate similar vulnerability to pathogenic Ala53Thr human alpha-syn toxicity.

Authors:  Chenere P Ramsey; Elpida Tsika; Harry Ischiropoulos; Benoit I Giasson
Journal:  Hum Mol Genet       Date:  2010-01-20       Impact factor: 6.150

9.  BAG1 restores formation of functional DJ-1 L166P dimers and DJ-1 chaperone activity.

Authors:  Sebastian Deeg; Mathias Gralle; Kamila Sroka; Mathias Bähr; Fred Silvester Wouters; Pawel Kermer
Journal:  J Cell Biol       Date:  2010-02-15       Impact factor: 10.539

Review 10.  Mitochondrial quality control and neurological disease: an emerging connection.

Authors:  Inês Pimenta de Castro; L Miguel Martins; Roberta Tufi
Journal:  Expert Rev Mol Med       Date:  2010-04-19       Impact factor: 5.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.